Displaying 1 - 78 of 78 tests
ALK for Lymphoma

Probes: ALK (2p23)
Disease(s): Anaplastic large cell lymphoma, NHL

FISH
ALK-1 (for heme cases)The ALK1 (ALK1 cline) antibody labels normal human ALK protein and the NPM-ALK chimeric protein, and is a useful tool for the identification of the subgroup of anaplastic large-cell lymphomas (ALCL) that are ALK positive. Immunohistochemistry (IHC)
API2/MALT1 t(11;18)Probes: API2/MALT1 t(11;18)
Disease(s): MALT lymphoma, NHL
FISH
B-Cell Gene Rearrangement

Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of New York.

Molecular
B-Cell Lymphoma Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are CD5, CD10, CD11c, CD19, CD20, CD23, CD45, FMC-7, kappa, and lambda.

Flow Cytometry
BCL1 Translocation, t(11;14)

Real-time PCR for quantitative detection of t(11;14) BCL1/IgH rearrangements. Analytical sensitivity is approximately 1 tumor cell in 1000 normal cells. Positive results are reported as a ratio between quantities of (11;14) DNA and a normal control gene. This translocation is also known as CCND1/IgH or BCL1/JH.

Molecular
BCL1/Cyclin D1BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections and is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator possibly by mediating the growth stimulatory effects of hormone receptor signaling. It has been found to play a major role in both breast and prostate tumorigenesis. Nuclear overexpression of BCL1 has been shown to increase the chance of prostate cancer metastasis to bone, and has been associated with poor prognosis. High nuclear expression of BCL1 is usually associated with poor prognosis. Immunohistochemistry (IHC)
BCL2Probes: BCL2 (18q21)
Disease(s): B-cell lymphoma, non-Hodgkin lympoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)
FISH
BCL2B-cell lymphoma 2 (BCL2) was the first of the translocation-associated proteins to be identified in lymphoma. Most cases of follicular lymphoma have a [t(14;18)] translocation, resulting in BCL2 overexpression. Overexpression of BCL2 in activated diffuse B-cell lymphoma may predict disease progression. BCL2 is also expressed in a wide range of other neoplasms. Immunohistochemistry (IHC)
BCL2 Translocation, t(14;18)

PCR and fragment analysis for quantitative detection of IGH-BCL2 translocations associated with 70-80% of follicular lymphoma and approximately 20% of diffuse large B-cell lymphoma. Translocations involving the major (MBR), minor (MCR), and 3' MBR sub-cluster regions of BCL2 are analyzed. Positive results quantify the ratio of mutant BCL2 to internal control DNA. Testing may be performed on plasma to increase sensitivity.

Molecular
BCL6BCL6 antibody stains the germinal center cells in lymphoid follicles, the follicular cells and interfollicular cells in follicular lymphoma, a subset of diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of Reed-Sternberg cells in nodular lymphocyte predominant Hodgkin lymphoma. In contrast, BCL6 rarely stains mantle cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma. BCL6 expression is seen in approximately half of CD30+ anaplastic large cell lymphomas but is absent in other peripheral T-cell lymphomas. Immunohistochemistry (IHC)
BCL6 (3q27)Probes: BCL6 (3q27)
Disease(s): Diffuse large B-cell lymphoma, NHL
FISH
CCND1(BCL1)/IgH t(11;14)Probes: CCND1/IgH t(11;14)
Disease(s): Mantle cell lymphoma, NHL
FISH
CD10CD10, also known as Common Acute Lymphocytic Leukemia Antigen (CALLA), is expressed in early lymphoid progenitors and normal germinal center cells. It is almost always present on the surface of precursor B-lymphoblastic and Burkitt lymphomas and much less frequently on precursor T-lymphoblastic leukemia-lymphoma. Many follicular lymphoma and some diffuse large B-cell lymphomas, along with multiple myeloma are positive. CD10 is also present on breast myoepithelial cells, bile canaliculi, fibroblasts and with especially high expression on the brush border of kidney and gut epithelial cells. CD10 is also a good marker of endometrial stomal sarcoma. Immunohistochemistry (IHC)
CD138CD138 (Syndecan-1) positively stains normal tissue including B-cell precursors and plasma cells. Positive staining in tumors includes myeloma, primary effusion lymphoma. CD138 negative staining comprises mature B-cells and lymphomas (even plasmacytoid lymphomas). Many carcinomas also express CD138. Immunohistochemistry (IHC)
CD15CD15 (X-Hapten) plays a role in mediating phagocytosis, bactericidal activity, and chemotaxis. It is present on granulocytes, including neutrophils and eosinophils, and to a lesser degree on monocytes. CD15 is also expressed in Reed-Sternberg cells and some epithelial cells. CD15 antibody is useful in the identification of Hodgkin lymphoma. CD15 is occasionally expressed in large cell lymphomas of both B- and T- phenotypes. Immunohistochemistry (IHC)
CD19CD19 recognizes a 95kD cell surface glycoprotein which is expressed by cells of the B-cell lineage and follicular dendritic cells. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders. Immunohistochemistry (IHC)
CD2CD2, the E-rosette receptor, is an extremely broad T-cell marker. This antibody immunostains the vast majority of T-cells and a subset of natural killer (NK) - cell malignancies. Half of thymic B-cells are also CD2 positive. Immunohistochemistry (IHC)
CD20Normal cell expression of CD20 is found on most B-cells (after CD19 and CD10 expression, before CD21/22 expression and surface immunoglobulin expression) and expression is retained on mature B-cells until plasma cell development, as well as ollicular dendritic cells. In diseased cells, there is positive staining on most B-cell lymphomas, come pre-acute B lymphoblastic leukemia/ lymphoblastic lymphoma (B-ALL/LBL); lymphocyte predominant Hodgkin lymphoma, dimly expressed in T-cells (benign and neoplastic), and spindle cell thymomas. Rixtuximab treated patients may lose CD20 positivity in B cell lymphomas. Immunohistochemistry (IHC)
CD21CD21 (CR2, C3d receptor and EBV receptor) is expressed strongly on mature B-cells, follicular dendritic cells (FDC) and weakly on immature thymocytes and T-lymphocytes. In B-cell ontogeny, CD21 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. Immunohistological analysis of FDC in paraffin sections of Non-Hodgkin lymphoma (NHL) with this antibody demonstrates a nodular and usually dense and sharply defined FDC meshwork in follicular lymphomas and a loose, ill-defined FDC of varying size in some diffuse lymphoma types. Precursor B-cell lymphoma (lymphoblastic lymphomas), Burkitt lymphomas, plasmacytomas and hairy cell leukemias consistently lack CD21 expression. CD21 is expressed on follicular dendritic cell sarcoma. Immunohistochemistry (IHC)
CD22CD22 expression is restricted to normal and neoplastic B-cells and is absent from other hemopoietic cell types. In B-cell ontogeny, CD22 is first expressed in the cytoplasm of pro-B and pre-B-cells and on the surface as B-cells mature to become IgD+. It is not expressed by plasma cells. CD22 is found highly expressed in follicular, mantle and marginal zone B-cells, while germinal center B-cells are relatively weak. Its expression roughly parallels that of CD19. It is strongly expressed in hairy cell leukemia. Immunohistochemistry (IHC)
CD23CD23 is identical to low affinity IgE receptor found on B-cells. CD23 is expressed on a subpopulation of peripheral blood cells, B-lymphocytes and on EBV transformed B-lymphoblastoid cell lines. CD23 is most useful in distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from other entities and may remain present in CLL/SLL that has undergone large cell transformation. Immunohistochemistry (IHC)
CD25The interleukin-2 receptor is designated CD25. Originally isolated from T-lymphocytes, it is now known to be expressed on hairy cell leukemia and adult T-cell leukemia/lymphoma, classical Hodgkin lymphoma, and a subset of other peripheral T-cell lymphomas. Immunohistochemistry (IHC)
CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3. Immunohistochemistry (IHC)
CD30CD30 is a lymphocyte activation antigen, related to tumor necrosis factor. It is expressed in activated B-, T- and NK cells. Positive staining is seen in infectious mononucleosis, lymphocytes infected with HIV, HTLV-1, EBV, HHV8 or hepatitis B, Reed-Sternberg cells, anaplastic large cell lymphomas (90%), lymphomatoid papulosis, peripheral T-cell lymphomas, and embryonal cell tumors. Immunohistochemistry (IHC)
CD34CD34, a single chain transmembrane glycoprotein, is selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells and endothelial cells. CD34 antibody labels many gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans, solitary fibrous tumor and a subset of sarcomas. CD34 staining has been also used to measure angiogenesis. Immunohistochemistry (IHC)
CD43CD43 (leukosialin, sialophorin, or leukocyte sialoglycoprotein) is a cell surface glycoprotein that is expressed on all thymocytes, T-cells, and cells of myeloid lineage. CD43 antibody can be useful in the diagnosis of T-cell lymphoma and a subset of B-cell lymphoma. CD43 expression in lymphomas is highly correlated with CD5; thus, most T-cell malignancies and a group of small lymphocyte B-cell malignancies (CLL/SLL, mantle cell lymphoma, and prolymphocytic leukemia (PLL)) are often positive, whereas follicular lymphoma is rarely positive. CD43 is also positive in about 50% of cases of Burkitt lymphoma. Immunohistochemistry (IHC)
CD45 (LCA)CD45 (Leukocyte Common Antigen, LCA) is comprised of at least four isoforms (CD45RA, CD45RB, CD45RC and CD45RO) of membrane glycoproteins. CD45 is expressed on hematopoietic cells (human leukocytes, including lymphocytes, monocytes, and eosinophils), but is absent on normal and malignant non-hematopoietic tissues. Immunohistochemistry (IHC)
CD45ROCD45RO (an isoform of leukocyte common antigen) reacts with mature activated T-cells, most thymocytes, and a sub-population of resting T-cells within both CD4 and CD8 subsets. CD45RO antibody marks many T-cell lymphomas but also identifies granulocytes, histiocytes and some B-cells. It rarely stains B-cell lymphomas. Immunohistochemistry (IHC)
CD5CD5, a transmembrane protein, is found on most thymocytes and immature peripheral T-cells. It stains normal B-cells of mantle zone of spleen and lymph nodes, B-cells in peritoneal and pleural cavities, and almost all T-cells. In a fetus, most B-cells in spleen and cord blood are CD5 positive. It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies, and most thymic carcinomas. CD5 is usually negative in spindle cell thymoma. Immunohistochemistry (IHC)
CD56CD56 recognizes two proteins of the neural cell adhesion molecule, the basic molecule expressed on most neuroectodermally-derived cell lines, tissues and neoplasms (e.g. retinoblastoma, medulloblastomas, astrocytomas, and neuroblastomas). It is also expressed on some mesodermally-derived tumors (rhabdomyosarcoma) and on natural killer cells. CD56 can be used as a marker for NK cell neoplasms. Some benign and malignant plasma cells are also positive. CD56 is often positive in neuroendocrine carcinomas. Immunohistochemistry (IHC)
CD57CD57 is expressed on subpopulations of peripheral blood mononuclear cells, NK active cells and T-cells. Hematopoietic malignancies that are CD57+ include a minority of T-lymphoblastic leukemias, roughly three quarters of the indolent T-cell large granular lymphocytic leukemias, and a small portion of NK-cell lymphomas. It can be used to highlight small lymphoid cells in nodular lymphocytic predominant Hodgkin lymphoma. Immunohistochemistry (IHC)
CD7CD7 is expressed on the majority of immature and mature T-lymphocytes and T-cell leukemia. It is also found on natural killer cells, and a small subpopulation of normal and malignant B-cells. CD7 antibody can be useful for detection of T-cell leukemias and myeloid leukemias. CD7 expression is often lost in mycosis fungoides. Immunohistochemistry (IHC)
CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells. Immunohistochemistry (IHC)
CD79B Mutation Analysis

Bi-directional sequencing of exon 5 of the CD79B gene which includes detection of the common Y196 mutations. Testing is available separately or as part of the NeoTYPE™ Lymphoma Profile.

Molecular
CD8CD8 is a T-cell marker for the detection of cytotoxic/suppressor T-cells. CD8 is also detected on NK cells, most thymocytes, a subpopulation of null cells, and bone marrow cells. This antibody is useful in evaluating T-cell lymphomas. Immunohistochemistry (IHC)
Chromosome Analysis

A wide variety of abnormalities can be identified, providing both diagnostic and prognostic information. Acute leukemias, lymphomas and chronic myeloid and lymphoid disorders are examined cytogenetically in order to establish the exact nature of the acquired genetic change. Rearrangements, also known as translocations, inversions, and deletions, can usually be detected under a light microscope. In most leukemias and lymphomas, changes in chromosome number (ploidy) or chromosome structure (rearrangements) are often observed.
 

Cytogenetics
cMyccMyc protein is a transcription factor localized to the nucleus of the cell. Amplification of the cMyc gene has been found in several types of human tumors.

cMyc is amplified in 20-30% of breast cancer cases and is associated with HER-2 amplification and poor outcome. In Burkitt’s lymphoma, 90% of tumors have translocation of cMyc or variants. cMyc protein (>50%) is seen in a subset of cases of diffuse large B-cell lymphoma (DLBCL) and is correlated with Myc rearrangement. It is also positive in radiation-associated angiosarcoma.

Immunohistochemistry (IHC)
EBER

This probe set labels all latent EBV-infected cells, including EBV-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed-Sternberg cells in almost all EBV-associated Hodgkin lymphoma cases. Global interpretation is available on head and neck specimens only; tech-only testing is available for all samples.

In Situ Hybridization (ISH)
EBV (LMP1)This antibody reacts strongly with Epstein Barr Virus (EBV)-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with some EBV-associated neoplasms, particularly EBV-associated Hodgkin lymphoma. Immunohistochemistry (IHC)
EMAEpithelial Membrane Antigen (EMA) antibody stains normal and neoplastic cells from various tissues, including mammary epithelium, sweat glands and squamous epithelium. Hepatocellular carcinoma, adrenal carcinoma and embryonal carcinomas are consistently EMA negative, therefore, keratin positivity with negative EMA favors one of these tumors. EMA is frequently positive in meningioma, which can be useful when distinguishing it from other intracranial neoplasms, e.g. Schwannomas. The absence of EMA can also be of value since negative EMA is characteristic of tumors such as adrenal carcinoma, seminomas, paraganglioma and hepatoma. Immunohistochemistry (IHC)
EZH2 Mutation Analysis

Bi-directional sequencing of exons 3-13 and 15-18 of the EZH2 gene.

Molecular
FOXP1FOX P1 (Forkheadbox-P1) is a transcription factor widely expressed in normal tissues. Its expression is commonly deregulated in malignancies. FOX P1 is differentially expressed in resting and activated B cells. FOX P1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCL) and is more common in the non-germinal center (non-GC), activated B-cell type. Loss of FOX P1 expression has been correlated with a poor prognosis in solid tumors, such as breast cancer. In contrast, high level expression of smaller isoforms of the FOX P1 protein identifies high risk patients with DLBCL. The study demonstrated a correlation between strong nuclear positivity and poor prognosis in a subset of patients with BCL2-positive, [t(14;18)]-negative, non-GC DLBCL. Immunohistochemistry (IHC)
GCET1The GCET1 gene codes for a serpin expressed in germinal center (GC) B-cells. GCET1 is highly restricted to a subset of GC B-cells and GC-derived lymphomas. It is preferentially expressed in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with GC B-cell differentiation. Immunohistochemistry (IHC)
HGALHGAL is specifically expressed in the cytoplasm of germinal center B-cells, but is absent in mantle and marginal zone. This antibody is highly specific for germinal center B-cells and it is an ideal marker for the detection of germinal center-derived B-cell lymphomas. Immunohistochemistry (IHC)
High-Grade B-Cell Lymphoma Reflex FISH Panel (Non-New York)

Probes: MYC (8q24). If rearranged, reflex to concurrent BCL2 (18q21) and BCL6 (3q27).
Disease(s): B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma

Note: This test is available on a global basis. Tech-only clients may order probes individually.

FISH
High-Grade/Large B-Cell Lymphoma Panel (NY and non-NY)

Probes: BCL6 (3q27) | MYC (8q24) | IgH/BCL2 t(14;18) | Optional probes: MYC/IgH/CEN8 t(8;14) [available to all clients] and BCL2 (18q21) [non-New York clients only]
Disease(s): B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma

FISH
IgDIgD antibody reacts with immunoglobulin Ig delta chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas (in particular marginal zone lymphoma). Cytoplasmic staining is easily identified on paraffin tissue. IgD staining is also seen in normal mantle zone B-lymphocytes. Immunohistochemistry (IHC)
IgGIgG antibody reacts with immunoglobulin Ig gamma chains. This antibody may be useful in identifying plasma cytomas and B-cell lineage lymphomas, and in conjunction with IgG4 staining to assess for IgG4 associated disease. Immunohistochemistry (IHC)
IgH (14q32)

Probes: IgH (14q32)
Disease(s): Lymphoma, NHL, multiple myeloma, MGUS

FISH
IgH Clonality/MRD by NGS

The IgH Clonality/MRD by NGS assay detects clonal populations of B-lymphocytes in a given patient sample through the analysis of the VDJ segment of the immunoglobulin heavy chain (IgH) gene. *Note - Baseline testing of the original primary sample will need to be performed prior to testing on new samples submitted for monitoring of minimal residual disease.

Molecular
IgH/BCL2 t(14;18)Probes: IgH/BCL2 t(14;18)
Disease(s): Follicular lymphoma, NHL
FISH
IgM

IgM antibody reacts with immunoglobulin Ig mu chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas.

Immunohistochemistry (IHC)
KappaAntibody to the kappa light chain of immunoglobulin is reportedly useful in the identification of leukemias, plasmacytomas and certain non-Hodgkin lymphomas. Demonstration of monotypism in lymphoid infiltrates is a surrogate for clonality, and therefore malignancy. Immunohistochemistry (IHC)
KappaEach test contains a set of oligonucleotide probes. The intended target is the kappa light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations. In Situ Hybridization (ISH)
Ki67

Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
Note: Computer-assisted image analysis for Ki-67 is only validated for breast cancer and neuroendocrine carcinoma.

Immunohistochemistry (IHC)
Lambda

Each test contains a set of oligonucleotide probes. The intended target is the lambda light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations.

In Situ Hybridization (ISH)
Low-Grade/Small B-Cell Lymphoma FISH Panel

Probes: BCL6 (3q27) | CCND1/IgH t(11;14) IgH/BCL2 t(14;18) | MALT1 (18q21)
Probes may be ordered separately.
Disease(s): NHL, B-Cell Lymphoma, MCL, follicular lymphoma, MZL, MALT lymphoma

FISH
MALT1 (18q21)

Probes: MALT1 (18q21)
Disease(s): Marginal zone B-cell lymphoma, NHL

FISH
MUM1The MUM1 antibody is specific for the MUM1/IRF4 protein that is overexpressed in late plasma-cell-directed stages of B-cell differentiation. MUM1 is a powerful tool for understanding the histogenesis of B-cell lymphomas. MUM1 protein is an excellent marker for Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma in combination with CD30. Furthermore, MUM1 seems to be a marker of prognostic value since it has been found that the expression of MUM1 is associated with the poor prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry (IHC)
MYC (8q24)Probes: MYC (8q24)
Disease(s): Lymphoma, NHL, B-ALL
FISH
MYC/IgH/Cen 8 t(8;14)Probes: Trisomy 8 (Cen 8) | MYC/IgH t(8;14)
Disease(s): Burkitt lymphoma, NHL
FISH
MYD88 Mutation Analysis

Bi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation.

Molecular
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Cytogenetics
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Molecular
NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile

The NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile is performed by the sequencing of select exons in the genes IDH1, IDH2, DNMT3A, TET2 and RHOA

Molecular
NeoTYPE Lymphoma Profile

This test is performed by multiple methods to detect mutations in the following genes BCL1, BCL2, BRAF, CARD11, CD79B, EZH2, MYD88 and NRAS. The test is performed by sequencing the entire coding regions of the genes listed unless otherwise noted. BCL1/ IgH translocation t(11;14) is performed by real-time PCR and BCL2  t(14;18) is performed by fragment length analysis. Test orders include summary interpretation of all results together.

Molecular
Non-Hodgkin's Lymphoma (NHL) FISH Panel

Probes: ALK (2p23) | BCL6 (3q27) | MYC (8q24) | CCND1/IgH t(11;14) | IgH (14q32) | IgH/BCL2 t(14;18) | MALT1 (18q21)
Probes may be ordered separately.
Disease(s): NHL

FISH
PAX5Paired Box 5 (PAX5) is a B-cell specific activator protein (BSAP). In early stages of B-cell development, PAX5 influences the expression of several B-cell specific genes, such as CD19 and CD20. PAX5 is expressed primarily in pro-, pre-, and mature B-cells, but not in plasma cells. There is an excellent correlation between CD20 and PAX5 expression; however, anti-PAX5 exceeds the specificity and sensitivity of L26 (CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B-cells, including classic Hodgkin lymphoma. It is very specific to B-cell lineage and does not stain T-cells. Immunohistochemistry (IHC)
PD1Programmed death-1 (PD-1) is expressed on activated T-cells, B-cells, and myeloid cells. Anti-PD-1 is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PD-1 is expressed by few B-cells, so anti-PD-1 may be a more specific and useful diagnostic marker in angioimmunoblastic lymphoma. In addition, PD-1 expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells. PD-1 expression in angioimmunoblastic lymphoma lends further support to this model of T-cell oncogenesis, in which specific subtypes of T-cells may undergo neoplastic transformation and result in specific distinct histologic, immunophenotypic, and clinical subtypes of T-cell neoplasia. Programmed Death 1 (PD1) is expressed on most T-cells and a small subset of B-cells in the light zone of germinal centers and is a useful marker of angioimmunoblastic lymphoma. Immunohistochemistry (IHC)
Standard Leukemia/Lymphoma Panel - 24 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.

Flow Cytometry
T&B Tissue Flow Panel

Stand-alone test. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD34, CD38, CD45, CD56, kappa, and lambda (17 markers). 

Flow Cytometry
T-Cell Receptor Beta Gene Rearrangement

This test provides qualitative detection of monoclonal T-cell receptor (TCR) beta gene rearrangements by PCR and fragment analysis according to BIOMED-2 consensus primer design. This test may be ordered concurrently with or after negative results in our T-Cell Receptor Gamma Gene Rearrangement assay for gamma gene rearrangements to improve TCR rearrangement detection by ~5% in T-cell leukemias/lymphomas. 

Molecular
T-Cell Receptor Gamma Gene Rearrangement

Detection of clonal T-cell receptor gamma (TCRG) gene rearrangements by PCR of variable and joining regions. T-Cell Receptor Beta Gene Rearrangement is offered separately and may be added to this gamma gene test.

Molecular
TP53 Mutation Analysis

Bi-directional sequencing of TP53 exons 4-9.

Molecular
Universal Fusion/Expression Profile

The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.

Molecular
V-Beta T-Cell Clonality

Available as global test only. Markers are VB1, VB2, VB3, VB4, VB5.1, VB5.2, VB5.3, VB7.1, VB7.2, VB8, VB9, VB11, VB12, VB13.1, VB13.2, VB13.6, VB14, VB16, VB17, VB18, VB20, VB21.3, VB22, and VB23 (24 markers). Two additional T-cell markers are used to identify the population of interest and the markers vary from case to case.

Flow Cytometry
Wright GiemsaSpecial stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology. Immunohistochemistry (IHC)